Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury

Ericka L. Fink, Yichen Lai, Xiaopeng Zhang, Keri Janesko-Feldman, P. David Adelson, Csaba Szabo, Rachel P. Berger, Ajit A. Sarnaik, Patrick M. Kochanek, Robert S B Clark

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Poly-ADP-ribosylation (PAR) of proteins by poly(ADP-ribose) polymerases (PARP) occurs after experimental traumatic brain injury (TBI) and modulates neurologic outcome. Several promising pharmacological PARP inhibitors have been developed for use in humans, but there is currently no clinically relevant means of monitoring treatment effects. We therefore used an enzyme-linked immunosorbent assay to measure PAR-modified proteins in cerebrospinal fluid (CSF). Cerebrospinal fluid samples from 17 pediatric TBI patients and 15 controls were plated overnight and then incubated with polyclonal antibody against PAR. Histone-1, a PARP substrate, was incubated with active PARP, NAD, and nicked DNA, and served as the standard. Both peak and mean CSF PAR-modified proteins were increased in TBI patients versus controls. Peak CSF PAR-modified protein levels occurred on day 1 and levels remained increased on day 2 after TBI. Increases in peak CSF PAR-modified protein concentrations were independently associated with age and male sex, but not initial Glasgow Coma Scale score, Glasgow outcome score, or mechanism of injury. The increase in PAR-modified proteins in CSF after TBI may be because of increased PARP activation, decreased PAR degradation, or both. As PAR-modified protein concentration correlated with age and male sex, developmental and sex-dependent roles for PARP after TBI are implicated.

Original languageEnglish (US)
Pages (from-to)1523-1529
Number of pages7
JournalJournal of Cerebral Blood Flow and Metabolism
Volume28
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Poly Adenosine Diphosphate Ribose
Cerebrospinal Fluid Proteins
Adenosine Diphosphate
Poly(ADP-ribose) Polymerases
Cerebrospinal Fluid
Proteins
Traumatic Brain Injury
Glasgow Coma Scale
NAD
Histones
Nervous System
Enzyme-Linked Immunosorbent Assay
Pharmacology
Pediatrics

Keywords

  • ADP-ribosyltransferase
  • Biomarker
  • Enzyme-linked immunosorbent assay
  • Head injury
  • Poly(ADP-ribose) synthetase
  • Poly(ADPribose) polymerase

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury. / Fink, Ericka L.; Lai, Yichen; Zhang, Xiaopeng; Janesko-Feldman, Keri; Adelson, P. David; Szabo, Csaba; Berger, Rachel P.; Sarnaik, Ajit A.; Kochanek, Patrick M.; Clark, Robert S B.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 28, No. 9, 09.2008, p. 1523-1529.

Research output: Contribution to journalArticle

Fink, EL, Lai, Y, Zhang, X, Janesko-Feldman, K, Adelson, PD, Szabo, C, Berger, RP, Sarnaik, AA, Kochanek, PM & Clark, RSB 2008, 'Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury', Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 9, pp. 1523-1529. https://doi.org/10.1038/jcbfm.2008.52
Fink, Ericka L. ; Lai, Yichen ; Zhang, Xiaopeng ; Janesko-Feldman, Keri ; Adelson, P. David ; Szabo, Csaba ; Berger, Rachel P. ; Sarnaik, Ajit A. ; Kochanek, Patrick M. ; Clark, Robert S B. / Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury. In: Journal of Cerebral Blood Flow and Metabolism. 2008 ; Vol. 28, No. 9. pp. 1523-1529.
@article{b9350b194a8e49f1907e9309c89b5bb9,
title = "Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury",
abstract = "Poly-ADP-ribosylation (PAR) of proteins by poly(ADP-ribose) polymerases (PARP) occurs after experimental traumatic brain injury (TBI) and modulates neurologic outcome. Several promising pharmacological PARP inhibitors have been developed for use in humans, but there is currently no clinically relevant means of monitoring treatment effects. We therefore used an enzyme-linked immunosorbent assay to measure PAR-modified proteins in cerebrospinal fluid (CSF). Cerebrospinal fluid samples from 17 pediatric TBI patients and 15 controls were plated overnight and then incubated with polyclonal antibody against PAR. Histone-1, a PARP substrate, was incubated with active PARP, NAD, and nicked DNA, and served as the standard. Both peak and mean CSF PAR-modified proteins were increased in TBI patients versus controls. Peak CSF PAR-modified protein levels occurred on day 1 and levels remained increased on day 2 after TBI. Increases in peak CSF PAR-modified protein concentrations were independently associated with age and male sex, but not initial Glasgow Coma Scale score, Glasgow outcome score, or mechanism of injury. The increase in PAR-modified proteins in CSF after TBI may be because of increased PARP activation, decreased PAR degradation, or both. As PAR-modified protein concentration correlated with age and male sex, developmental and sex-dependent roles for PARP after TBI are implicated.",
keywords = "ADP-ribosyltransferase, Biomarker, Enzyme-linked immunosorbent assay, Head injury, Poly(ADP-ribose) synthetase, Poly(ADPribose) polymerase",
author = "Fink, {Ericka L.} and Yichen Lai and Xiaopeng Zhang and Keri Janesko-Feldman and Adelson, {P. David} and Csaba Szabo and Berger, {Rachel P.} and Sarnaik, {Ajit A.} and Kochanek, {Patrick M.} and Clark, {Robert S B}",
year = "2008",
month = "9",
doi = "10.1038/jcbfm.2008.52",
language = "English (US)",
volume = "28",
pages = "1523--1529",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury

AU - Fink, Ericka L.

AU - Lai, Yichen

AU - Zhang, Xiaopeng

AU - Janesko-Feldman, Keri

AU - Adelson, P. David

AU - Szabo, Csaba

AU - Berger, Rachel P.

AU - Sarnaik, Ajit A.

AU - Kochanek, Patrick M.

AU - Clark, Robert S B

PY - 2008/9

Y1 - 2008/9

N2 - Poly-ADP-ribosylation (PAR) of proteins by poly(ADP-ribose) polymerases (PARP) occurs after experimental traumatic brain injury (TBI) and modulates neurologic outcome. Several promising pharmacological PARP inhibitors have been developed for use in humans, but there is currently no clinically relevant means of monitoring treatment effects. We therefore used an enzyme-linked immunosorbent assay to measure PAR-modified proteins in cerebrospinal fluid (CSF). Cerebrospinal fluid samples from 17 pediatric TBI patients and 15 controls were plated overnight and then incubated with polyclonal antibody against PAR. Histone-1, a PARP substrate, was incubated with active PARP, NAD, and nicked DNA, and served as the standard. Both peak and mean CSF PAR-modified proteins were increased in TBI patients versus controls. Peak CSF PAR-modified protein levels occurred on day 1 and levels remained increased on day 2 after TBI. Increases in peak CSF PAR-modified protein concentrations were independently associated with age and male sex, but not initial Glasgow Coma Scale score, Glasgow outcome score, or mechanism of injury. The increase in PAR-modified proteins in CSF after TBI may be because of increased PARP activation, decreased PAR degradation, or both. As PAR-modified protein concentration correlated with age and male sex, developmental and sex-dependent roles for PARP after TBI are implicated.

AB - Poly-ADP-ribosylation (PAR) of proteins by poly(ADP-ribose) polymerases (PARP) occurs after experimental traumatic brain injury (TBI) and modulates neurologic outcome. Several promising pharmacological PARP inhibitors have been developed for use in humans, but there is currently no clinically relevant means of monitoring treatment effects. We therefore used an enzyme-linked immunosorbent assay to measure PAR-modified proteins in cerebrospinal fluid (CSF). Cerebrospinal fluid samples from 17 pediatric TBI patients and 15 controls were plated overnight and then incubated with polyclonal antibody against PAR. Histone-1, a PARP substrate, was incubated with active PARP, NAD, and nicked DNA, and served as the standard. Both peak and mean CSF PAR-modified proteins were increased in TBI patients versus controls. Peak CSF PAR-modified protein levels occurred on day 1 and levels remained increased on day 2 after TBI. Increases in peak CSF PAR-modified protein concentrations were independently associated with age and male sex, but not initial Glasgow Coma Scale score, Glasgow outcome score, or mechanism of injury. The increase in PAR-modified proteins in CSF after TBI may be because of increased PARP activation, decreased PAR degradation, or both. As PAR-modified protein concentration correlated with age and male sex, developmental and sex-dependent roles for PARP after TBI are implicated.

KW - ADP-ribosyltransferase

KW - Biomarker

KW - Enzyme-linked immunosorbent assay

KW - Head injury

KW - Poly(ADP-ribose) synthetase

KW - Poly(ADPribose) polymerase

UR - http://www.scopus.com/inward/record.url?scp=50249120577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249120577&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2008.52

DO - 10.1038/jcbfm.2008.52

M3 - Article

VL - 28

SP - 1523

EP - 1529

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 9

ER -